The effects of physiological changes in estrogens and androgens on the erythrocyte antioxidant superoxide dismutase, catalase and glutathione peroxidase enzyme activities during the menstrual cycle were investigated in healthy eumenorrheic women. Blood samples were taken on alternate days from twelve normally cyclic women (age range: 20 to 27 years; mean age: 24·1 years) from the first day of one menstrual cycle until the first day of the subsequent one. Plasma was analyzed for FSH, LH, estradiol, progesterone, testosterone, free testosterone and androstenedione concentrations. Erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities were evaluated on the same days and cycle length was standardized on the basis of the preovulatory estradiol peak. Significant cyclic phase-related changes were observed in glutathione peroxidase (P<0·05), with higher glutathione peroxidase activity levels from the late follicular to the early luteal phase compared with those found in the early follicular phase (P<0·001 and P<0·002 respectively). A significant positive correlation was observed between mean estradiol and glutathione peroxidase cycle-related variations (r=0·80, P<0·001), whereas no significant cycle phase-dependent changes were seen in superoxide dismutase and catalase. No effect of progesterone and androgens on the erythrocyte antioxidant enzyme system was documented. The findings indicate that physiological ovarian estradiol production during the menstrual cycle may have an important role in regulating erythrocyte glutathione peroxidase activity.
Introduction
Reactive oxygen species (ROS) have been implicated as major initiators of tissue damage and can upregulate enzyme activity, signal transcription, and gene expression (Palmer & Paulson 1977 , Sen & Packer 1996 . Antioxidant defences, made up of intracellular and extracellular components, work synergistically to maintain an optimal redox balance. Detoxification of superoxide anion and hydrogen peroxide, catalyzed by intracellular superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) enzyme activities represents a major line of defence (Gutteridge 1995) .
ROS play a number of significant, diverse roles in female reproductive biology including uterine environment, oocyte maturation and ovulation, corpus luteum function and regression (Riley & Behrman 1991) . Estrogens have been shown to have in vitro antioxidant effects on membrane phospholipid peroxidation (Sugioka et al. 1987) and experimental evidence indicates an antioxidant and atheroprotective role (Yagi & Komura 1986 , Huber et al. 1990 , Subbiah et al. 1993 , Sack et al. 1994 , Arnal et al. 1996 . The relationship between sex steroid hormones and the cellular antioxidant enzyme system has also been investigated. In prolonged oral contraceptive use, increased GSH-Px (Capel et al. 1981 , Massafra et al. 1993 and CAT (Massafra et al. 1996) erythrocyte activities have been reported. In amenorrheic women, estradiol (E 2 ) (Massafra et al. 1996 (Massafra et al. , 1997 , but not progestagen (Massafra et al. 1997) , replacement therapy has been proven to stimulate erythrocyte GSH-Px activity. The aim of the present study was to examine the relationship between physiological variations in estrogens and androgens and the erythrocyte SOD, CAT and GSH-Px enzyme activities during the menstrual cycle.
Materials and Methods

Subjects
Twelve healthy nulliparous volunteers (age range: 20 to 27 years; mean age: 24·1 years), with a history of regular menstrual cycles lasting from 28 to 30 days were examined. The healthy status was confirmed by history, physical examination and laboratory data. Body mass index was within normal limits (BMI: 21·4 1·6 kg/m   2   , range  19-22·5 kg/m 2 ), and all subjects were on a standard balanced Mediterranean diet. None of the subjects had smoking habits or a history of intensive exercise. None had made use of oral contraceptives for at least one year before the study, or any other type of medication during the previous four months or during the study period. Informed consent was obtained prior to participation in the study.
Study design
All subjects participated in the study during the same period. The study covered the period from the first day (M) of one menstrual cycle to the first day of the subsequent cycle. Plasma levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), E 2 , progesterone, testosterone, free testosterone, androstenedione and erythrocyte SOD, CAT and GSH-Px activities were evaluated every other day in all subjects. Erythrocyte pyruvate kinase (PK) activity, as a red cell age-dependent marker (Grimes 1980) , was also determined on the same days. Cycle length was standardized on the basis of the preovulatory E 2 peak (day 0), and values were given for the first day of a menstrual phase (M), and days 12, 10, 8, 6, 4, 2, 0, 2, 4, 6, 8, 10, 12, 14 of the menstrual cycle. Follicular and luteal phases were defined on the basis of the pattern of the hormone levels and were divided into six different groups: early (from M to day 10), mid (from days 8 to 4) and late (from days 2 to 0) follicular phase and early (from days 2 to 4), mid (from days 6 to 10) and late (from days 12 to 14) luteal phase.
Assays
Blood samples (12 ml) were taken from the antecubital vein between 0800 and 0900 h after overnight fasting, and collected into heparinized tubes. Blood was immediately centrifuged (3000 r.p.m. for 10 min at 4 C), and aliquots of the plasma samples were stored at 30 C until hormonal assay. Erythrocytes were immediately washed three times in normal saline solution, deprived of buffycoats, and stored at 80 C until the enzyme activity assay was performed. Both hormone and enzyme assessments were performed in a single matrix, at the end of the study period. FSH and LH (Radim, Pomezia, Roma, Italy) were determined by immunoradiometric assay (IRMA). Estradiol, progesterone, testosterone (Sorin Biomedica, Saluggia, Vercelli, Italy), free testosterone (Diagnostic System Laboratories, Inc., Webster, TX, USA) and androstenedione (Radim) were determined by radioimmunoassay (RIA). Sensitivity and precision data of the hormone assays are reported in Table 1 . Accuracy data of the assays were as reported by the manufacturers. SOD activity was assayed by the method of Beauchamp & Fridovich (1973) . GSH-Px, CAT and PK activities were determined by Beutler's method (Beutler 1986) . Precision data enzyme activities were tested using ten replicate assays at three different concentrations of hemolysate samples and eleven replicate assays at three different concentrations of blood samples over 3 days, and assuming the limit of sensitivity to represent a change in absorbance at 340 nm of 0·001 per min with a concentration of 12·0 g/Hb. Analytical accuracy data for the assays are reported in Table 1 . (1994) (1995) , DataMost Co., Salt Lake City, UT, USA). Significant associations between variables were determined using regression analysis. To identify the temporal relationships between cycle-related steroid changes and erythrocyte antioxidant activities, the variables were analyzed by time-series analysis (Box & Jenkins 1976) , using the statistical software package SPSS for Windows (1989) (1990) (1991) (1992) (1993) (1994) 
Results
The mean duration of the menstrual cycle was 29 1·0 (mean ..) days (28-30 days), with menses duration of 4·0 1·3 days (mean ..). All the women examined had a regular ovulatory cycle, as indicated by hormonal patterns. Cycle phase-related changes in FSH, LH, E 2 , progesterone, testosterone, free testosterone and androstenedione are shown in Table 2 , while changes in SOD, CAT, GSH-Px and PK are shown in Table 3 . Significant cycle-dependent changes were observed in GSH-Px activity (P<0·05), with higher GSH-Px levels from the late follicular to early luteal phases as compared with values found in the early follicular phase (P<0·001 and P<0·002 respectively). A significant positive correlation between E 2 and GSH-Px was observed (r=0·80, P<0·001). A time series analysis showed a significant positive contemporaneous relationship between E 2 and GSH-Px cycle-related changes, with no significant time delays (lags) to the relationship (Fig. 1) . Conversely, no significant correlations were seen between E 2 plasma levels and variations in SOD, CAT and PK activities. No significant correlations were seen between FSH, LH, progesterone, testosterone, free testosterone or androstenedione plasma levels and variations in SOD, CAT, GSH-Px and PK activities. 
Discussion
The present study demonstrates a positive significant relationship between physiological cyclic changes in E 2 plasma levels and variations in erythrocyte GSH-Px activity during the menstrual cycle. The observed changes in GSH-Px activity were unrelated to erythrocyte population age, as no significant cyclic changes in erythrocyte PK activity were present. Conversely, no significant changes were seen during the cycle in SOD and CAT erythrocyte activities and no significant correlation was seen between these enzyme activities and FSH, LH, E 2 , progesterone, testosterone, free testosterone and androstenedione plasma concentration variations. These results appear to confirm our previous findings in hypothalamic amenorrheic patients regarding the stimulation of erythrocyte GSH-Px activity (Massafra et al. 1996 (Massafra et al. , 1997 , but not SOD and CAT activities (Massafra et al. 1997) , following monthly E 2 -transdermal patch therapy at physiological concentrations, but not following progestagen therapy.
Significantly lower GSH-Px activity has been seen in both endometrial tissue and blood samples from late menopausal women, compared with that seen in premenopausal women (Gurdol et al. 1997) . In addition, erythrocyte GSH-Px activity is higher in women than in men (Guemouri et al. 1991) and hepatic GSH-Px activity is higher in female than in male rats (Prohaska & Sunde 1993) , indicating a sex-related difference in the antioxidative defence system. Likewise, a study for determining the relative ranking of antioxidative potential of 14 steroid compounds showed that only E 2 , 17 -estradiol and estriol are naturally occurring antioxidants (Mooradian 1993) . Other steroids tested, such as progesterone, testosterone and androstenedione, had no significant antioxidant properties (Mooradian 1993) . Taken as a whole, our findings suggest that ovarian E 2 production may play an important antioxidant role, acting on the regulation of erythrocyte GSH-Px. The existence of a relationship between cellular enzyme antioxidant activity and ovarian steroid activity has also been demonstrated in vitro. A positive correlation between GSH-Px activity and in vitro E 2 production by human ovaries incubated with FSH, and an inverse correlation between E 2 and lipid peroxide production with aging have been reported (Sagara 1989 ). This hypothesis is also supported by the finding of lower serum lipid peroxide levels in normal premenopausal women compared with normal postmenopausal subjects Figure 1 Cross-correlation between E 2 plasma levels and erythrocyte GSH-Px activity during the menstrual cycle. *A significant positive contemporaneous correlation (at lag 0) was found between the two series (r=0·80, P<0·001). Broken lines represent 95% confidence limits. CCF: cross-correlation function. S.E.: standard error of the mean. (Asada et al. 1990) . Moreover, bilateral ovariectomy has been shown significantly to increase serum lipid peroxides in premenopausal women (Asada et al. 1990) .
Estrogens, like vitamin E, possess ROS-scavenging chain-breaking antioxidant activity as hydrogen donors from their phenol-hydroxyl ring (Sugioka et al. 1987 ). The positive relationship between E 2 plasma levels and GSH-Px erythrocyte activity during the menstrual cycle further supports the hypothesis that the antioxidant activity of estrogens may also be a consequence of a modulation of GSH-Px enzyme activity by an increase in the GSH-Px transcription (Massafra et al. 1997) . This may be the result of an effect of this hormone on bone marrow erythroblast maturation with stimulation of the synthesis of active new GSH-Px molecules. Although allosteric activation regulating the GSH-Px activity (Perona et al. 1978 ) may be another possible interpretation of these findings, the evidence for the existence of allosteric forms of the enzyme remains highly controversial.
These observations appear to be of importance, in consideration of the protective role of these hormones in the pathogenesis of atherosclerosis (Castelli 1984 , Knopp 1986 ) and cardiovascular disease (Van der Schouw et al. 1996) . Menopause (Van der Schouw et al. 1996) , and bilateral ovariectomy prior to menopause (Parrish et al. 1967) , both result in an increased risk of myocardial infarction and coronary atherosclerosis in women. Furthermore, estrogen replacement in postmenopausal women has been shown to have antioxidant effects based on scavenging mechanism (Sack et al. 1994) , and cardioprotective effects (Stampfer et al. 1991) . In particular, estrogen decreases oxidative modification of low-density lipoproteins both in vitro and in vivo (Ayres et al. 1998) . Furthermore, beneficial effects of estrogen in Alzheimer's disease have been reported and may be partly attributable to its potent antioxidant activity (Paganini-Hill 1996) .
Our results document a rise in GSH-Px activity during the menstrual cycle, which is particularly evident from the late follicular to the early luteal phase, a period in which there is the maximum ovarian production of estrogen. Future studies will aim to clarify whether this statistically significant relationship results in a biologically protective role of specific reproductive functions.
